Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An Argentine woman appears to be free of HIV long after stopping treatment.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
A new CDC model shows that more treatment and less PrEP Would slash new HIV cases by 94%.
If left untreated, hepatitis B and C can lead to cirrhosis and liver cancer.
Lenacapavir shows promise for long-acting HIV treatment and prevention.
Here’s a closer look at some of the available COVID-19 treatments and how to get more information about them and others.
While people with HIV have a higher rate of early Alzheimer’s than those without the virus, treatment appears to eliminate this excess risk.
People with untreated HIV in a recent study had signs of faster cell aging, which treatment reduced but did not eliminate.
Switching to an integrase inhibitors is not tied to gain in bad fat, according to recent study.
A small subset of people living with HIV are able to control viral replication without antiretroviral treatment.
HIV organizations and groups look forward to 2021 and closing in on the goal of ending HIV.
A recent study sheds light on weight gain after switching to new form of tenofovir.
The HIV regimen failed only a few study participants.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
Findings confirm that Trogarzo maintains viral load suppression for nearly 10 years.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.